Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single‐arm, open‐label, phase 3 study

• Published in: Therapeutic apheresis and dialysis Vol. 26; no. 2; pp. 368 - 377
• Main Authors: Akizawa, Tadao, Nobori, Kiyoshi, Matsuda, Yoshimi, Taki, Kentaro, Hayashi, Yasuhiro, Hayasaki, Takanori, Yamamoto, Hiroyasu
• Format: Journal Article
• Language: English
• Published: Kyoto, Japan John Wiley & Sons Australia, Ltd 01.04.2022
• Subjects: anemia; Anemia - drug therapy; Anemia - etiology; erythropoiesis; Erythropoietin - therapeutic use; Hematinics; Hemoglobins - analysis; Humans; Japan; Original; Peritoneal Dialysis - adverse effects; Pyrazoles; renal dialysis; Renal Dialysis - adverse effects; renal insufficiency; Renal Insufficiency, Chronic - therapy; Treatment Outcome; Triazoles; Japan; erythropoiesis; renal insufficiency; anemia; renal dialysis

This 36‐week, open‐label, single‐arm, phase 3 study investigated the safety and efficacy of molidustat in Japanese patients with renal anemia undergoing peritoneal dialysis. Molidustat was titrated every 4 weeks to maintain Hb levels within the target range (≥11.0 and <13.0 g/dL). The primary eff...